Latest & greatest articles for asthma

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on asthma or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on asthma and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for asthma

141. Diagnosis and Management of Asthma in Adults: A Review. (Abstract)

Diagnosis and Management of Asthma in Adults: A Review. Asthma affects about 7.5% of the adult population. Evidence-based diagnosis, monitoring, and treatment can improve functioning and quality of life in adult patients with asthma.Asthma is a heterogeneous clinical syndrome primarily affecting the lower respiratory tract, characterized by episodic or persistent symptoms of wheezing, dyspnea, and cough. The diagnosis of asthma requires these symptoms and demonstration of reversible airway (...) obstruction using spirometry. Identifying clinically important allergen sensitivities is useful. Inhaled short-acting β2-agonists provide rapid relief of acute symptoms, but maintenance with daily inhaled corticosteroids is the standard of care for persistent asthma. Combination therapy, including inhaled corticosteroids and long-acting β2-agonists, is effective in patients for whom inhaled corticosteroids alone are insufficient. The use of inhaled long-acting β2-agonists alone is not appropriate. Other

2017 JAMA

142. Information and communication technology use in asthmatic patients: a cross-sectional study in Latin America Full Text available with Trip Pro

Information and communication technology use in asthmatic patients: a cross-sectional study in Latin America Rapid diffusion, low cost and broad availability of information and communication technologies (ICTs) make them an attractive platform for managing care, communication and interventions in asthma. There is little information in Latin America about usage frequency of ICTs in asthmatic patients. The analysis undertaken consisted of an observational, cross-sectional study that aimed (...) to identify the frequency and type of ICTs most often used by asthmatics. The Spanish version of the Michigan questionnaire was employed in five Latin American countries. Age and educational level was categorised. Logistic regression was performed among these groups concerning the frequency of ICT usage and the level of interest shown in seeking and receiving information about asthma. In total, 673 asthma patients were surveyed. The mean age was 43.44 years. Over two-thirds of the participants were female

2017 ERJ open research

143. Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): a randomised, double-blind, placebo-controlled trial. (Abstract)

Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): a randomised, double-blind, placebo-controlled trial. Exacerbations of asthma cause a substantial global illness burden. Adults with uncontrolled persistent asthma despite maintenance treatment require additional therapy. Since macrolide antibiotics can be used to treat persistent asthma, we aimed to assess the efficacy and safety of oral azithromycin as add-on therapy (...) in patients with uncontrolled persistent asthma on medium-to-high dose inhaled corticosteroids plus a long-acting bronchodilator.We did a randomised, double-blind, placebo controlled parallel group trial to determine whether oral azithromycin decreases the frequency of asthma exacerbations in adults (≥18 years) with symptomatic asthma despite current use of inhaled corticosteroid and long-acting bronchodilator, and who had no hearing impairment or abnormal prolongation of the corrected QT interval

2017 Lancet Controlled trial quality: predicted high

144. Variations in the prevalence of childhood asthma and wheeze in MeDALL cohorts in Europe Full Text available with Trip Pro

Variations in the prevalence of childhood asthma and wheeze in MeDALL cohorts in Europe While there is evidence for variations in prevalence rates of childhood wheeze and asthma between countries, longitudinal, individual-level data are needed to understand these differences. The aim of this study was to examine variations in prevalence rates of childhood asthma, wheeze and wheeze with asthma in Europe. We analysed datasets from 10 MeDALL (Mechanisms of the Development of ALLergy) cohorts (...) in eight countries, representing 26 663 children, to calculate prevalence rates of wheeze and asthma by child age and wheeze with asthma at age 4 years. Harmonised variables included outcomes parent-reported wheeze and parent-reported doctor-diagnosed asthma, and covariates maternal education, parental smoking, pets, parental asthma, doctor-diagnosed allergic rhinitis, doctor-diagnosed eczema and wheeze severity. At age 4 years, asthma prevalence varied from 1.72% in Germany to 13.48% in England

2017 ERJ open research

145. An evidence-based, point-of-care tool to guide completion of asthma action plans in practice Full Text available with Trip Pro

An evidence-based, point-of-care tool to guide completion of asthma action plans in practice Asthma action plans (AAPs) reduce healthcare utilisation, improve quality of life and are recommended across guidelines. However, fewer than 25% of patients receive an AAP, partly due to prescribers' inability to complete "yellow zone" instructions (how to intensify therapy for acute loss of control). We sought to review best evidence to develop a practical, evidence-based tool to facilitate yellow zone (...) guidance in adults.We reviewed recent asthma guidelines and adult studies addressing acute loss of asthma control (January 2010 to March 2016). We developed evidence-based rules for yellow zone therapy and operational guidelines to maximise adherence and minimise errors.We reviewed three guidelines and 11 manuscripts (2486 abstracts screened). Recommendations were comparable but some areas lacked guidance. For 15/43 asthma regimens, the commonly recommended four- to five-fold yellow zone inhaled

2017 EvidenceUpdates

146. [Reslizumab (severe eosinophilic asthma) - Benefit assessment according to õ 35a Social Code Book V]

[Reslizumab (severe eosinophilic asthma) - Benefit assessment according to õ 35a Social Code Book V] Reslizumab (Asthma): Nutzenbewertung gemäß § 35a SGB V; Dossierbewertung; Auftrag A17-02 [Reslizumab (severe eosinophilic asthma) – Benefit assessment according to § 35a Social Code Book V] Reslizumab (Asthma): Nutzenbewertung gemäß § 35a SGB V; Dossierbewertung; Auftrag A17-02 [Reslizumab (severe eosinophilic asthma) – Benefit assessment according to § 35a Social Code Book V] Institut für (...) Qualität und Wirtschaftlichkeit im Gesundheitswesen Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Reslizumab (Asthma): Nutzenbewertung gemäß § 35a SGB V; Dossierbewertung; Auftrag A17-02. [Reslizumab (severe eosinophilic asthma) – Benefit assessment according to § 35a Social Code

2017 Health Technology Assessment (HTA) Database.

147. [Fractional exhaled nitric oxide measurement in patients with asthma and chronic cough]

[Fractional exhaled nitric oxide measurement in patients with asthma and chronic cough] [Fractional exhaled nitric oxide measurement in patients with asthma and chronic cough] [Fractional exhaled nitric oxide measurement in patients with asthma and chronic cough] Virgilio S, Bardach A, Pichon-Riviere A, Augustovski F, García Martí S, Alcaraz A, Ciapponi A Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation (...) of the quality of this assessment has been made for the HTA database. Citation Virgilio S, Bardach A, Pichon-Riviere A, Augustovski F, García Martí S, Alcaraz A, Ciapponi A. [Fractional exhaled nitric oxide measurement in patients with asthma and chronic cough] Buenos Aires: Institute for Clinical Effectiveness and Health Policy (IECS). Documentos de Evaluación de Tecnologías Sanitarias, Informe de Respuesta Rapida No 536. 2017 Authors' conclusions Moderate quality evidence suggests that fractional exhaled

2017 Health Technology Assessment (HTA) Database.

148. A pharmacy management service for adults with asthma: a cluster randomised controlled trial Full Text available with Trip Pro

A pharmacy management service for adults with asthma: a cluster randomised controlled trial Although clinical guidelines are available for the management of asthma, this health condition is still poorly managed in many countries.To assess the effects of a Pharmacy Management Service (PharMS) on asthma control of adult patients.This study comprised of a cluster randomised controlled trial (RCT) that was conducted from April 2014 to July 2015 at four government health clinics. The control (...) participants received usual pharmacy service, while the intervention participants were recruited into the PharMS. Each participant was monitored for 6 months, and the outcome measures included asthma control using the Asthma Control Test (ACT), inhaler technique using a checklist and medication adherence using the Malaysian Medication Adherence Scale.A total of 157 participants were recruited: 77 in the control and 80 in the intervention group. At the end of the study, 90% of the intervention participants

2017 EvidenceUpdates

149. Oral Glucocorticoid-Sparing Effect of Benralizumab in Severe Asthma. Full Text available with Trip Pro

Oral Glucocorticoid-Sparing Effect of Benralizumab in Severe Asthma. Many patients with severe asthma rely on oral glucocorticoids to manage their disease. We investigated whether benralizumab, a monoclonal antibody directed against the alpha subunit of the interleukin-5 receptor that significantly reduces the incidence of asthma exacerbations, was also effective as an oral glucocorticoid-sparing therapy in patients relying on oral glucocorticoids to manage severe asthma associated (...) with eosinophilia.In a 28-week randomized, controlled trial, we assessed the effects of benralizumab (at a dose of 30 mg administered subcutaneously either every 4 weeks or every 8 weeks [with the first three doses administered every 4 weeks]) versus placebo on the reduction in the oral glucocorticoid dose while asthma control was maintained in adult patients with severe asthma. The primary end point was the percentage change in the oral glucocorticoid dose from baseline to week 28. Annual asthma exacerbation

2017 NEJM Controlled trial quality: predicted high

150. KIT Inhibition by Imatinib in Patients with Severe Refractory Asthma. Full Text available with Trip Pro

KIT Inhibition by Imatinib in Patients with Severe Refractory Asthma. Mast cells are present in the airways of patients who have severe asthma despite glucocorticoid treatment; these cells are associated with disease characteristics including poor quality of life and inadequate asthma control. Stem cell factor and its receptor, KIT, are central to mast-cell homeostasis. We conducted a proof-of-principle trial to evaluate the effect of imatinib, a KIT inhibitor, on airway hyperresponsiveness (...) , a physiological marker of severe asthma, as well as on airway mast-cell numbers and activation in patients with severe asthma.We conducted a randomized, double-blind, placebo-controlled, 24-week trial of imatinib in patients with poorly controlled severe asthma who had airway hyperresponsiveness despite receiving maximal medical therapy. The primary end point was the change in airway hyperresponsiveness, measured as the concentration of methacholine required to decrease the forced expiratory volume in 1

2017 NEJM Controlled trial quality: predicted high

151. Do Inhaled Anticholinergic Agents in Addition to ß-Agonists Improve Outcomes in Acute Asthma Exacerbations?

Do Inhaled Anticholinergic Agents in Addition to ß-Agonists Improve Outcomes in Acute Asthma Exacerbations? TAKE-HOME MESSAGE The addition of inhaled anticholinergic agents to b-2 agonists reduced hospitalization and improved pulmonary function testing, but was also associated with increased rates of mild adverse events. Do Inhaled Anticholinergic Agents in Addition to b-Agonists Improve Outcomes in Acute Asthma Exacerbations? EBEM Commentators Michael Gottlieb, MD Matthew J. Kuhns, MD (...) 2017 Annals of Emergency Medicine 421exacerbations (relative risk 0.56; 95% con?dence interval 0.43 to 0.72), with no signi?cant difference noted in mild (relative risk 1.88; 95% con?dence interval 0.37 to 9.54) or moderate (relative risk 0.88; 95% con?dence interval 0.69 to 1.11) exacerbations. Commentary Asthma is a common disease, affectingmorethan17.7million adults in the United States. 2 Asthma exacerbations result in 1.8 million annual ED visits in the United States, with 11.9

2017 Annals of Emergency Medicine Systematic Review Snapshots

152. Positive Expiratory Pressure for the Treatment of Acute Asthma Exacerbations: A Randomized Controlled Trial (Abstract)

Positive Expiratory Pressure for the Treatment of Acute Asthma Exacerbations: A Randomized Controlled Trial To evaluate the efficacy of brief, single administration of positive expiratory pressure (PEP) therapy in reducing clinical severity and need for additional second-line therapies and hospitalization in children presenting to the emergency department (ED) with acute asthma.This was a prospective randomized controlled trial of children 2-18 years of age presenting to a tertiary-care (...) academic pediatric ED with moderate-to-severe asthma exacerbations from December 2014 to June 2016. Children who continued to have moderate asthma severity after completion of initial therapies (albuterol/ipratropium bromide and corticosteroids) were randomized to receive PEP therapy or standard of care. The primary outcome was change in pulmonary asthma score before and after intervention, as assessed by a blinded physician. Secondary outcomes included need for additional therapies, ED length of stay

2017 EvidenceUpdates

153. CRACKCast E073 – Asthma

with beta agonists. Only recommended to maintain people on it if they are on it in the community Empiric antibiotics – you guessed it. With signs of overt infection (eg lobular pneumonia) not helpful. Possible that high procalcitonin levels may reflect bacterial infection Nebulized furosemide – thought to help exercised induced asthma, but no data to support its use [5] Discuss a ventilation strategy for the critically-ill asthmatic patient Induction agent: Ketamine/Propofol/Etomidate. No benefit (...) CRACKCast E073 – Asthma CRACKCast E073 - Asthma - CanadiEM CRACKCast E073 – Asthma In , by Adam Thomas April 27, 2017 This episode of CRACKCast covers Rosen’s Chapter 73, Asthma. Not just for kids! This disease process is satisfying to treat when patients respond well to therapy, but recognition of critically-ill patients is an important first step in management. Shownotes – Rosens in Perspective Basic Principles: Reverse Obstruction Treat Hypoxia Treat Inflammation Basic definition : A chronic

2017 CandiEM

154. Asthma education for school staff. Full Text available with Trip Pro

Asthma education for school staff. Teachers and school staff should be competent in managing asthma in schools. Demonstrated low levels of asthma knowledge mean that staff may not know how best to protect a child with asthma in their care, or may fail to take appropriate action in the event of a serious attack. Education about asthma could help to improve this knowledge and lead to better asthma outcomes for children.To assess the effectiveness and safety of asthma education programmes (...) for school staff, and to identify content and attributes underpinning them.We conducted the most recent searches on 29 November 2016.We included randomised controlled trials comparing an intervention to educate school staff about asthma versus a control group. We included studies reported as full text, those published as abstract only and unpublished data.At least two review authors screened the searches, extracted outcome data and intervention characteristics from included studies and assessed risk

2017 Cochrane

155. Can we use the combination formoterol-budesonide in teenagers with moderate or severe asthma?

Can we use the combination formoterol-budesonide in teenagers with moderate or severe asthma? Can we use the combination formoterol-budesonide in teenagers with moderate or severe asthma? - Evidencias en pediatría Searching, please wait Show menu Library Management You did not add any article to your library yet. | Search Evidence-Based decision making Evidence-Based decision making Show menu Library Management You did not add any article to your library yet. × User Password Log in × Reset (...) password If you need to reset your password please enter your email and click the Send button. You will receive an email to complete the process. Email Send × Library Management × March 2017. Volume 13. Number 1 Can we use the combination formoterol-budesonide in teenagers with moderate or severe asthma? Rating: 0 (0 Votes) Reviewers: , . | Newsletter Free Subscription Regularly recieve most recent articles by e-mail Subscribe × Newsletter subscription: Email Confirm email I accept the journal’s

2017 Evidencias en Pediatría

156. Antibiotics for Acute Asthma Exacerbations: Clinical Effectiveness, Cost-Effectiveness, and Guidelines

and four evidence based guidelines were identified regarding the use of antibiotics for acute asthma exacerbations. Tags asthma, amoxicillin, anti-bacterial agents, azithromycin, cefazolin, cefuroxime, clindamycin, erythromycin, fluoroquinolones, penicillins, vancomycin, Asthma, Asthmas, asthmatic, asthmatics, Severe, acute, exacerbation, Antibiotic, Antibiotics, anti-bacterial Files Rapid Response Summary of Abstracts Published : March 23, 2017 Related Content Follow us: © 2019 Canadian Agency (...) Antibiotics for Acute Asthma Exacerbations: Clinical Effectiveness, Cost-Effectiveness, and Guidelines Antibiotics for Acute Asthma Exacerbations: Clinical Effectiveness, Cost-Effectiveness, and Guidelines | CADTH.ca Find the information you need Antibiotics for Acute Asthma Exacerbations: Clinical Effectiveness, Cost-Effectiveness, and Guidelines Antibiotics for Acute Asthma Exacerbations: Clinical Effectiveness, Cost-Effectiveness, and Guidelines Published on: March 23, 2017 Project Number

2017 Canadian Agency for Drugs and Technologies in Health - Rapid Review

157. Lungs deposition and pharmacokinetic study of submicron budesonide particles in Wistar rats intended for immediate effect in asthma Full Text available with Trip Pro

Lungs deposition and pharmacokinetic study of submicron budesonide particles in Wistar rats intended for immediate effect in asthma The purpose of the present investigation was to study the aerosolization, lungs deposition and pharmacokinetic study of inhalable submicron particles of budesonide in male Wistar rats. Submicron particles were prepared by antisolvent nanoprecipitation method and freeze-dried to obtain free flowing powder. The freeze-drying process yielded dry powder with desirable

2017 EXCLI journal

158. SQ HDM SLIT-tablet for house dust mite allergic asthma

SQ HDM SLIT-tablet for house dust mite allergic asthma SQ HDM SLIT-tablet for house dust mite allergic asthma | Innovation Observatory toggle menu Menu Search View All Filter by Speciality Filter by Year Filter by Category This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required (...) for our stakeholders. > > > SQ HDM SLIT-tablet for house dust mite allergic asthma SQ HDM SLIT-tablet for house dust mite allergic asthma March 2017 Innovation Observatory Voice Leave a Reply Your email address will not be published. Required fields are marked * Post Comment Name * Email * Website PDF Report Connect to the Innovation Observatory Twitter Related Posts October 2018 Apremilast works by suppressing the activity of inflammatory pathway caused by molecules such as interleukins and tumour

2017 NIHR Innovation Observatory

159. Asthma in adolescence affects daily life and school attendance – Two cross‐sectional population‐based studies 10 years apart Full Text available with Trip Pro

Asthma in adolescence affects daily life and school attendance – Two cross‐sectional population‐based studies 10 years apart The aim of this study was to study the impact of asthma on daily life, school absenteeism and physical education. In addition, to describe asthma triggers at school.Two cross-sectional population-based studies ten years apart.Within the OLIN-studies, in 2003 (n = 3,327) and in 2013 (n = 2,345) adolescents (14-15 years) answered an expanded ISAAC questionnaire (...) . Of these, 8% and 11%, respectively with current asthma participated in this study.Between the years 2003-2013, the proportion of adolescents reporting that asthma interfered with daily life had increased, in 2013, girls were significantly more affected than boys. The proportion reporting a worsening of asthma at school had decreased, but it was still over a quarter. The proportion of absenteeism from school and from physical education was at the same level both years. Asthma triggers were described

2017 Nursing open

160. Effect of an Integrated Pest Management Intervention on Asthma Symptoms Among Mouse-Sensitized Children and Adolescents With Asthma: A Randomized Clinical Trial. Full Text available with Trip Pro

Effect of an Integrated Pest Management Intervention on Asthma Symptoms Among Mouse-Sensitized Children and Adolescents With Asthma: A Randomized Clinical Trial. Professionally delivered integrated pest management (IPM) interventions can reduce home mouse allergen concentrations, but whether they reduce asthma morbidity among mouse-sensitized and exposed children and adolescents is unknown.To determine the effect of an IPM intervention on asthma morbidity among mouse-sensitized and exposed (...) children and adolescents with asthma.Randomized clinical trial conducted in Baltimore, Maryland, and Boston, Massachusetts. Participants were mouse-sensitized and exposed children and adolescents (aged 5-17 years) with asthma randomized to receive professionally delivered IPM plus pest management education or pest management education alone. Enrollment occurred between May 2010 and August 2014; the final follow-up visit occurred on September 25, 2015.Integrated pest management consisted of application

2017 JAMA Controlled trial quality: predicted high